Is Anti-CD30 antibody-drug conjugate SGN-35 Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use Anti-CD30 antibody-drug conjugate SGN-35? Is Anti-CD30 antibody-drug conjugate SGN-35 safe for nursing mother and child? Does Anti-CD30 antibody-drug conjugate SGN-35 extracts into breast milk? Does Anti-CD30 antibody-drug conjugate SGN-35 has any long term or short term side effects on infants? Can Anti-CD30 antibody-drug conjugate SGN-35 influence milk supply or can Anti-CD30 antibody-drug conjugate SGN-35 decrease milk supply in lactating mothers?
Anti-CD30 antibody-drug conjugate SGN-35 lactation summary
- DrLact safety Score for Anti-CD30 antibody-drug conjugate SGN-35 is 3 out of 8 which is considered Low Risk as per our analyses.
- A safety Score of 3 indicates that usage of Anti-CD30 antibody-drug conjugate SGN-35 may cause some minor side effects in breastfed baby.
- Our study of different scientific research indicates that Anti-CD30 antibody-drug conjugate SGN-35 may cause moderate to no side effects in lactating mother.
- Most of scientific studies and research papers declaring usage of Anti-CD30 antibody-drug conjugate SGN-35 low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- While using Anti-CD30 antibody-drug conjugate SGN-35 We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About Anti-CD30 antibody-drug conjugate SGN-35 usage in lactation
Anticuerpo monoclonal conjugado con propiedades antineoplásicas. Indicado en linfoma de Hodgkin y linfoma anaplásico de células grandes refractarios o en recaída.Administración intravenosa, una dosis cada 3 semanas. A fecha de última actualización no encontramos datos publicados sobre su excreción en leche materna. Su elevadísimo peso molecular hace muy improbable su paso a leche en cantidad significativa. Por su naturaleza protéica es inactivado en tracto gastrointestinal, no absorbiéndose, por lo que su biodisponibilidad oral es prácticamente nula, salvo en prematuros y periodo neonatal inmediato en los que puede haber mayor permeabilidad intestinal.
Answer by DrLact: About Anti-CD30 antibody-drug conjugate SGN-35 usage in lactation
No information is available on the clinical use of brentuximab during breastfeeding. Because brentuximab is a large protein molecule with a molecular weight of about 153,000, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, Anti-CD30 antibody-drug conjugate SGN-35 should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be discontinued during brentuximab therapy.
Alternate Drugs
Omalizumab(Low Risk)
Rituximab(Low Risk)
Ustekinumab(Low Risk)
Bevacizumab(Low Risk)
Natalizumab(Low Risk)
Trastuzumab(Unsafe)
Certolizumab Pegol(Safe)
Denosumab(Low Risk)
Infliximab(Safe)
Ipilimumab(Unsafe)
Abciximab(Low Risk)
Basiliximab(Low Risk)
Belimumab(Low Risk)
Secukinumab(Low Risk)
Brentuximab Vedotin(Low Risk)
Nivolumab(Unsafe)
Cetuximab(Unsafe)
Ranibizumab(Safe)